Skip to main content

Table 3 Baseline characteristics of patients with high titers (OD ≥ 0.40) of anti-PF4/heparin antibody

From: Reduced induction of anti-PF4/heparin antibody in RA patients after total knee arthroplasty

  Rheumatoid arthritis Osteoarthritis
Postoperative seroconversion (OD ≥ 0.4) Postoperative seroconversion (OD ≥ 0.4)
Positive Negative   Positive Negative  
(n = 3) (n = 23) p value (n = 25) (n = 73) p value
Gender (male/female) 0/3 2/21 0.5950 6/19 12/61 0.286
Age (years), mean ± SD 67.7 ± 9.5 70.0 ± 805 0.6289 74.6 ± 6.1 74.3 ± 6.1 0.598
Disease duration (years) 14.0 ± 10.1 13.2 ± 8.2 0.7734    
BMI (kg/m2)       
 Mean ± SD 25.2 ± 1.0 25.8 ± 5.0 0.9360 27.5 ± 4.0 26.7 ± 4.0 0.628
History of venous thrombosis, n (%) 1 (33.3 %) 2 (8.7 %) 0.2090 0 4 (5.5 %) 0.301
Comorbidities
 Hypertension 2 (66.7 %) 18 (78.3 %) 0.6539 17 (68.0 %) 49 (67.1 %) 0.936
 Ischemic heart disease 0 0   2 (8.0 %) 4 (5.5 %) 0.482
 Diabetes 1 (33.3 %) 6 (26.1 %) 0.7901 8 (32.0 %) 14 (19.2 %) 0.185
 Cerebrovascular disease 1 (33.3 %) 1 (4.3 %) 0.0764 2 (8.0 %) 6 (8.2 %) 0.669
Operation time (min)
 Mean ± SD 88.0 ± 4.4 94.6 ± 22.4 0.8096 91.4 ± 21.8 94.4 ± 24.2 0.699
RF (titer IU/ml) 1/3 (17.3 ± 24.8) 14/23 (59.8 ± 73.7) 0.5558 0.1366 N/a N/a  
Anti-CCP Ab (titer U/ml) 0/3 (0.6 ± 0.0) 18/23 (246.2 ± 560.1) 0.0215 0.0209 N/a N/a  
CRP (mg/dl) 1.51 ± 1.09 1.24 ± 1.37 0.3086 N/a N/a  
Use of steroid 2 (66.7 %) 16 (69.6 %) 0.9185 N/a N/a  
Use of MTX 1 (33.3 %) 9 (39.1 %) 0.8461 N/a N/a  
Foot pump 2 (66.7 %) 11 (47.8 %) 0.5393 10 (40.0 %) 36 (49.3 %) 0.421
  1. anti-CCP Ab anti-citrullinated peptide antibody, BMI body mass index, CRP C-reactive protein, MTX methotrexate, N/a not applicable, OD optical density, PF4 platelet factor 4, RF rheumatoid factor